Shares of GH Research PLC (NASDAQ:GHRS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $45.00.
A number of research firms recently weighed in on GHRS. Wells Fargo & Company initiated coverage on GH Research in a research note on Monday, July 27th. They set an “overweight” rating and a $44.00 price target on the stock. Needham & Company LLC boosted their price objective on GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, August 6th. New Street Research set a $65.00 target price on GH Research in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research report on Friday, July 17th. Finally, Zacks Research upgraded GH Research from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th.
Read Our Latest Stock Analysis on GH Research
GH Research Trading Up 3.2%
GH Research (NASDAQ:GHRS – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. On average, research analysts forecast that GH Research will post -1.20 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. Royal Bank of Canada raised its holdings in shares of GH Research by 43.1% in the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after acquiring an additional 780 shares during the last quarter. North Star Investment Management Corp. purchased a new stake in shares of GH Research in the first quarter worth approximately $31,000. Farther Finance Advisors LLC lifted its holdings in shares of GH Research by 9,720.0% in the third quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock valued at $231,000 after purchasing an additional 9,720 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of GH Research during the second quarter valued at approximately $495,000. Finally, Renaissance Technologies LLC purchased a new position in shares of GH Research during the first quarter valued at approximately $290,000. 56.90% of the stock is owned by institutional investors.
GH Research Company Profile
GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel treatments for psychiatric and neurological disorders. The company’s research centers on mebufotenin, also known as 5-MeO-DMT, a psychedelic compound being evaluated through proprietary formulations and delivery methods designed to produce rapid-acting therapeutic effects.
GH Research’s lead investigational program, GH001, is an inhaled formulation of mebufotenin being studied for major depressive disorder, including treatment-resistant depression.
See Also
- Five stocks we like better than GH Research
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
